These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27846946)

  • 61. Apremilast is effective in controlling the progression of adult vitiligo: A case series.
    Majid I; Imran S; Batool S
    Dermatol Ther; 2019 Jul; 32(4):e12923. PubMed ID: 30977956
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
    Schafer P
    Biochem Pharmacol; 2012 Jun; 83(12):1583-90. PubMed ID: 22257911
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Purpura Annularis Telangiectodes of Majocchi Associated With the Initiation and Rechallenge of Apremilast for Psoriasis Vulgaris.
    Kalik JA; Friedman H; Bechtel MA; Gru AA; Kaffenberger BH
    JAMA Dermatol; 2017 Nov; 153(11):1197-1198. PubMed ID: 28793154
    [No Abstract]   [Full Text] [Related]  

  • 64. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The incidence of PUVA lentigines.
    Jung EG; Obert W
    Photodermatol; 1986 Feb; 3(1):46-7. PubMed ID: 3703703
    [No Abstract]   [Full Text] [Related]  

  • 66. Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    Br J Dermatol; 2019 Jan; 180(1):211-212. PubMed ID: 30120892
    [No Abstract]   [Full Text] [Related]  

  • 67. [Apremilast withdrawals more frequent in standard practice than in clinical trials].
    Schmutz JL
    Ann Dermatol Venereol; 2018 Apr; 145(4):309-310. PubMed ID: 29605438
    [No Abstract]   [Full Text] [Related]  

  • 68. Apremilast and adalimumab: a novel combination therapy for recalcitrant psoriasis.
    Danesh MJ; Beroukhim K; Nguyen C; Levin E; Koo J
    Dermatol Online J; 2015 Jun; 21(6):. PubMed ID: 26158370
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cutaneous hyperpigmentation induced by apremilast.
    Di Cesare A; Pescitelli L; Ricceri F; Lazzeri L; Prignano F
    Int J Dermatol; 2018 Apr; 57(4):473-474. PubMed ID: 29350406
    [No Abstract]   [Full Text] [Related]  

  • 70. Therapeutic development in psoriasis.
    Sobell JM; Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Apremilast and psoriasis in the real world: A retrospective case series.
    Dozier L; Bartos G; Kerdel F
    J Am Acad Dermatol; 2020 Jul; 83(1):221-222. PubMed ID: 31604095
    [No Abstract]   [Full Text] [Related]  

  • 72. Apremilast: a step forward in the treatment of psoriasis?
    van de Kerkhof PC
    Lancet; 2012 Aug; 380(9843):708-9. PubMed ID: 22748703
    [No Abstract]   [Full Text] [Related]  

  • 73. The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database.
    Persson R; Hagberg KW; Qian Y; Vasilakis-Scaramozza C; Jick S
    J Am Acad Dermatol; 2020 Jul; 83(1):271-274. PubMed ID: 32222448
    [No Abstract]   [Full Text] [Related]  

  • 74. Acral PUVA--induced pigmented macules.
    Cruz A; Sánchez JL
    Bol Asoc Med P R; 1990 Oct; 82(10):460-2. PubMed ID: 2080960
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Apremilast and Secukinumab Combined Therapy in a Patient With Recalcitrant Plaque Psoriasis.
    Rothstein BE; McQuade B; Greb JE; Goldminz AM; Gottlieb AB
    J Drugs Dermatol; 2016 May; 15(5):648-9. PubMed ID: 27168275
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Recurrent generalized pustular psoriasis possibly triggered by apremilast.
    Wang WM; Shu D; Jiang YY; Jin HZ
    Chin Med J (Engl); 2020 May; 133(10):1259-1260. PubMed ID: 32433065
    [No Abstract]   [Full Text] [Related]  

  • 77. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex.
    Schafer PH; Truzzi F; Parton A; Wu L; Kosek J; Zhang LH; Horan G; Saltari A; Quadri M; Lotti R; Marconi A; Pincelli C
    Cell Signal; 2016 Jul; 28(7):753-63. PubMed ID: 26806620
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Apremilast in the treatment of palmoplantar pustulosis : A case series].
    Frischhut N; Ratzinger G
    Hautarzt; 2021 Mar; 72(3):252-256. PubMed ID: 32876701
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Apremilast, beyond psoriasis as a therapeutic target.
    Ruiz-Villaverde R; Bueno-Rodriguez A; Tercedor-Sánchez J
    Med Clin (Barc); 2017 Jul; 149(1):42-43. PubMed ID: 28242122
    [No Abstract]   [Full Text] [Related]  

  • 80. [Apremilast: Beware of suicidal ideation and behaviour].
    Schmutz JL
    Ann Dermatol Venereol; 2017 Mar; 144(3):243-244. PubMed ID: 28238463
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.